TABLE 1

Posaconazole pharmacokinetic data and participant demographics

ParameterStudy 1aStudy 2b
Study typeControlled pharmacokinetic study of posaconazole-fosamprenavir interactionObservational study of posaconazole TDM
Study populationHealthy volunteersPatients treated with posaconazole
N2082
Posaconazole dosingDay 1, 200 mg; day 2, 200 mg twice a day; days 3–10, 400 mg twice a dayMultiple dosing: 160–1,200 mg total daily dose
No. of samples/dose intervalc111
Median age (range), in yrs38 (18–54)50 (18–79)
Median wt (range), in kg74 (44–104)71 (38–122)
Sex [no. (%)]
    Female9 (45)35 (43)
    Male11 (55)47 (57)
  • a Based on data reported in reference 21.

  • b Based on data reported in reference 6.

  • c For subjects in study 2, between 1 to 42 samples were measured per patient across separate dose intervals.